These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10854165)

  • 1. Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.
    Mörner A; Achour A; Norin M; Thorstensson R; Björling E
    Virus Res; 1999 Jan; 59(1):49-60. PubMed ID: 10854165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E; Chiodi F; Utter G; Norrby E
    J Immunol; 1994 Feb; 152(4):1952-9. PubMed ID: 8120399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
    Björling E; Broliden K; Bernardi D; Utter G; Thorstensson R; Chiodi F; Norrby E
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6082-6. PubMed ID: 2068087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic and immunogenic sites of HIV-2 glycoproteins.
    Chiodi F; Björling E; Samuelsson A; Norrby E
    Chem Immunol; 1993; 56():61-77. PubMed ID: 8452654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.
    Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
    Curr HIV Res; 2006 Apr; 4(2):229-37. PubMed ID: 16611061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
    Bckström M; Holmgren J; Schödel F; Lebens M
    Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
    Aguilar A; Carrazana Y; Duarte CA
    Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
    Laisney IL; Strosberg AD
    Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.